Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Transiently Alters the Morphology of Corneal Endothelial Cells
Ripasudil (Glanatec), a selective Rho-associated coiled coil-containing protein kinase (ROCK) inhibitor, was approved in Japan in September 2014 for the treatment of glaucoma and ocular hypertension. The purpose of this study was to investigate the effect of ripasudil eye drops on corneal endothelia...
Saved in:
Published in | Investigative ophthalmology & visual science Vol. 56; no. 12; pp. 7560 - 7567 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.11.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Ripasudil (Glanatec), a selective Rho-associated coiled coil-containing protein kinase (ROCK) inhibitor, was approved in Japan in September 2014 for the treatment of glaucoma and ocular hypertension. The purpose of this study was to investigate the effect of ripasudil eye drops on corneal endothelial morphology, as ROCK signaling is known to modulate the actin cytoskeleton.
Morphological changes in the corneal endothelium were evaluated in human subjects by specular and slit-lamp microscopy, following topical administration of ripasudil. We also used a rabbit model to evaluate the effect of ripasudil on clinical parameters of the corneal endothelium. Twenty-four hours after ripasudil application, corneal specimens were evaluated by phalloidin staining, immunohistochemical analysis, and electron microscopy.
Specular microscopy revealed morphological changes in human eyes, and slit-lamp microscopy showed guttae-like findings. The rabbit model showed morphological changes similar to those seen in human eyes after ripasudil administration. Electron microscopy demonstrated that these alterations are due to the formation of protrusions along the cell-cell borders, but this formation is transient. Expression of corneal endothelial function-related markers was not disrupted; corneal thickness and corneal volume were not changed; and no cell death was observed following ripasudil administration.
Ripasudil induces transient guttae-like findings in humans, most likely due to protrusion formation along intracellular borders caused by the reduction in actomyosin contractility of the corneal endothelial cells. No severe adverse effects were observed. Physicians should be aware that ROCK inhibitors can cause these guttae-like findings, to avoid misdiagnosing patients as having Fuchs endothelial corneal dystrophy. (www.umin.ac.jp/ctr number, UMIN000018340.). |
---|---|
AbstractList | Ripasudil (Glanatec), a selective Rho-associated coiled coil-containing protein kinase (ROCK) inhibitor, was approved in Japan in September 2014 for the treatment of glaucoma and ocular hypertension. The purpose of this study was to investigate the effect of ripasudil eye drops on corneal endothelial morphology, as ROCK signaling is known to modulate the actin cytoskeleton.
Morphological changes in the corneal endothelium were evaluated in human subjects by specular and slit-lamp microscopy, following topical administration of ripasudil. We also used a rabbit model to evaluate the effect of ripasudil on clinical parameters of the corneal endothelium. Twenty-four hours after ripasudil application, corneal specimens were evaluated by phalloidin staining, immunohistochemical analysis, and electron microscopy.
Specular microscopy revealed morphological changes in human eyes, and slit-lamp microscopy showed guttae-like findings. The rabbit model showed morphological changes similar to those seen in human eyes after ripasudil administration. Electron microscopy demonstrated that these alterations are due to the formation of protrusions along the cell-cell borders, but this formation is transient. Expression of corneal endothelial function-related markers was not disrupted; corneal thickness and corneal volume were not changed; and no cell death was observed following ripasudil administration.
Ripasudil induces transient guttae-like findings in humans, most likely due to protrusion formation along intracellular borders caused by the reduction in actomyosin contractility of the corneal endothelial cells. No severe adverse effects were observed. Physicians should be aware that ROCK inhibitors can cause these guttae-like findings, to avoid misdiagnosing patients as having Fuchs endothelial corneal dystrophy. (www.umin.ac.jp/ctr number, UMIN000018340.). PURPOSERipasudil (Glanatec), a selective Rho-associated coiled coil-containing protein kinase (ROCK) inhibitor, was approved in Japan in September 2014 for the treatment of glaucoma and ocular hypertension. The purpose of this study was to investigate the effect of ripasudil eye drops on corneal endothelial morphology, as ROCK signaling is known to modulate the actin cytoskeleton.METHODSMorphological changes in the corneal endothelium were evaluated in human subjects by specular and slit-lamp microscopy, following topical administration of ripasudil. We also used a rabbit model to evaluate the effect of ripasudil on clinical parameters of the corneal endothelium. Twenty-four hours after ripasudil application, corneal specimens were evaluated by phalloidin staining, immunohistochemical analysis, and electron microscopy.RESULTSSpecular microscopy revealed morphological changes in human eyes, and slit-lamp microscopy showed guttae-like findings. The rabbit model showed morphological changes similar to those seen in human eyes after ripasudil administration. Electron microscopy demonstrated that these alterations are due to the formation of protrusions along the cell-cell borders, but this formation is transient. Expression of corneal endothelial function-related markers was not disrupted; corneal thickness and corneal volume were not changed; and no cell death was observed following ripasudil administration.CONCLUSIONSRipasudil induces transient guttae-like findings in humans, most likely due to protrusion formation along intracellular borders caused by the reduction in actomyosin contractility of the corneal endothelial cells. No severe adverse effects were observed. Physicians should be aware that ROCK inhibitors can cause these guttae-like findings, to avoid misdiagnosing patients as having Fuchs endothelial corneal dystrophy. (www.umin.ac.jp/ctr number, UMIN000018340.). |
Author | Fullwood, Nigel J Koizumi, Noriko Okumura, Naoki Okazaki, Yugo Kinoshita, Shigeru Inoue, Ryota Nakano, Shinichiro |
Author_xml | – sequence: 1 givenname: Naoki surname: Okumura fullname: Okumura, Naoki organization: Department of Biomedical Engineering Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe, Japan – sequence: 2 givenname: Yugo surname: Okazaki fullname: Okazaki, Yugo organization: Department of Biomedical Engineering Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe, Japan – sequence: 3 givenname: Ryota surname: Inoue fullname: Inoue, Ryota organization: Department of Biomedical Engineering Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe, Japan – sequence: 4 givenname: Shinichiro surname: Nakano fullname: Nakano, Shinichiro organization: Department of Biomedical Engineering Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe, Japan – sequence: 5 givenname: Nigel J surname: Fullwood fullname: Fullwood, Nigel J organization: Biomedical and Life Sciences, School of Health and Medicine, Lancaster University, Lancaster, United Kingdom – sequence: 6 givenname: Shigeru surname: Kinoshita fullname: Kinoshita, Shigeru organization: Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan – sequence: 7 givenname: Noriko surname: Koizumi fullname: Koizumi, Noriko organization: Department of Biomedical Engineering Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe, Japan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26618648$$D View this record in MEDLINE/PubMed |
BookMark | eNpNkE1LxDAQhoOs6K569Co56qHaJG2aHpd1_UBFWNZzSdupjWSTmmmF_fd2_cLTvDDPvAzPjEycd0DIKYsvGZPZlfEfeMnSiGVKZXtkytKUR2mmxORfPiQzxLc45ozx-IAccimZkomaEly1Ppoj-sroHmr6YJxGoPeuNaXpfaDLLdDr4Dt6vjKdxqE29oKug3ZowPV2S-e2h4C0b4E--dC13vrXLfUNXfjgQFu6dLUft9aMeQHW4jHZb7RFOPmZR-TlZrle3EWPz7f3i_ljVCVS9VGW6brhohQ6rXNRJ3WScMarHKpUqhJyuVtJzYUsE56DYA1AxXc3iYxTpcQROf_u7YJ_HwD7YmOwGj_QDvyABcuEUiyRgo9o9I1WwSMGaIoumI0O24LFxc5zsfNcsLT48jzyZz_VQ7mB-o_-FSs-ATqtfEA |
CitedBy_id | crossref_primary_10_1016_j_preteyeres_2020_100863 crossref_primary_10_1097_ICO_0000000000002855 crossref_primary_10_1007_s00417_019_04283_5 crossref_primary_10_1055_a_1751_3411 crossref_primary_10_1007_s00417_024_06388_y crossref_primary_10_1089_jop_2016_0085 crossref_primary_10_1007_s10792_019_01198_2 crossref_primary_10_22603_ssrr_2019_0019 crossref_primary_10_1080_08820538_2022_2112698 crossref_primary_10_1097_ICU_0000000000000579 crossref_primary_10_1007_s40123_023_00699_9 crossref_primary_10_1364_BOE_510432 crossref_primary_10_1007_s12325_021_02023_y crossref_primary_10_1097_IJG_0000000000001507 crossref_primary_10_1089_jop_2018_0063 crossref_primary_10_1136_bjophthalmol_2019_315776 crossref_primary_10_1097_coa_0000000000000024 crossref_primary_10_5124_jkma_2019_62_9_497 crossref_primary_10_1002_cbic_201700547 crossref_primary_10_1007_s40266_024_01107_y crossref_primary_10_1177_11206721231178057 crossref_primary_10_1097_ICU_0000000000000346 crossref_primary_10_3390_cells12091307 crossref_primary_10_1111_vop_12736 crossref_primary_10_1080_14656566_2017_1408791 crossref_primary_10_1007_s40265_019_01130_z crossref_primary_10_1089_jop_2016_0028 crossref_primary_10_4103_IJO_IJO_1345_23 crossref_primary_10_1016_j_ajoc_2022_101287 crossref_primary_10_1080_13543776_2019_1653279 crossref_primary_10_1016_j_jcjo_2021_06_010 crossref_primary_10_1097_ICU_0000000000000748 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1167/iovs.15-17887 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1552-5783 |
EndPage | 7567 |
ExternalDocumentID | 10_1167_iovs_15_17887 26618648 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .55 .GJ 18M 2WC 34G 39C 53G 5GY 5RE ACGFO ACNCT ADBBV AENEX AFFNX AFOSN AI. ALMA_UNASSIGNED_HOLDINGS BAWUL CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P GROUPED_DOAJ GX1 N9A NPM OK1 P2P RHF RPM SJN TR2 TRV VH1 W8F WH7 WOQ WOW X7M ZGI ZXP AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c468t-77adf23b3a5d93d4d44212c9ec568be963b3a6a236b429e31feec2adf24605883 |
ISSN | 1552-5783 |
IngestDate | Wed Jul 24 14:37:04 EDT 2024 Fri Aug 23 02:18:56 EDT 2024 Sat Sep 28 08:00:36 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c468t-77adf23b3a5d93d4d44212c9ec568be963b3a6a236b429e31feec2adf24605883 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://eprints.lancs.ac.uk/id/eprint/77062/1/i1552_5783_56_12_7560.pdf |
PMID | 26618648 |
PQID | 1738814632 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_1738814632 crossref_primary_10_1167_iovs_15_17887 pubmed_primary_26618648 |
PublicationCentury | 2000 |
PublicationDate | 2015-11-01 |
PublicationDateYYYYMMDD | 2015-11-01 |
PublicationDate_xml | – month: 11 year: 2015 text: 2015-11-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Investigative ophthalmology & visual science |
PublicationTitleAlternate | Invest Ophthalmol Vis Sci |
PublicationYear | 2015 |
SSID | ssj0021120 |
Score | 2.4129765 |
Snippet | Ripasudil (Glanatec), a selective Rho-associated coiled coil-containing protein kinase (ROCK) inhibitor, was approved in Japan in September 2014 for the... PURPOSERipasudil (Glanatec), a selective Rho-associated coiled coil-containing protein kinase (ROCK) inhibitor, was approved in Japan in September 2014 for the... |
SourceID | proquest crossref pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 7560 |
SubjectTerms | Adult Animals Endothelium, Corneal - drug effects Endothelium, Corneal - ultrastructure Female Fuchs' Endothelial Dystrophy - drug therapy Fuchs' Endothelial Dystrophy - metabolism Fuchs' Endothelial Dystrophy - pathology Humans Immunohistochemistry Isoquinolines - administration & dosage Male Microscopy, Electron Middle Aged Ophthalmic Solutions Rabbits rho-Associated Kinases - antagonists & inhibitors Sulfonamides - administration & dosage |
Title | Rho-Associated Kinase Inhibitor Eye Drop (Ripasudil) Transiently Alters the Morphology of Corneal Endothelial Cells |
URI | https://www.ncbi.nlm.nih.gov/pubmed/26618648 https://search.proquest.com/docview/1738814632 |
Volume | 56 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3ra9swEBdZB2Nfxt7LXmgwxkZwG1u2bH8sbUe30g66FrpPRpbl2SSxgh-B9O_YH7yTZDvOtsK2L8ZItgx3P5_uTvdA6C1xmRtzTiyWxtp141kxpaFlkzTlXsLACtEBsmf0-NL9fOVdjUY_BlFLTR3v8us_5pX8D1dhDPiqsmT_gbP9ojAA98BfuAKH4fpXPD7PpNXRFxTHk7yAPQl--SyP4UctJ0drMTks5VL7CfIlq5pEuXxDU9JcZULO15N9dV5eaQX0VALVTVEmFaUhy0KXHS4SlaY1V771AzGfV0OFdlCnYyUmcpnVGZsvzBoKVau8arq8yw2IvsyaRaM7HIF4l7N8M86umWmk_a35LnvcFrLRjtfztaz7feSMzZhuHD75mqn0ziwv5dCJYXttNp_eg1rB64FR7JumNp1kNiXHOwQ6Aznre6YLwe8bAFVH0LlcVbvqKypWcvgc8G-50GhQiklATZXPXypud1O30G0HxJcKFDz8dNKb8aChTrtqrdTf2_qWqi3dvr2t6NxgvWgt5uI-uteaH3jfYOkBGoniIbpz2gZYPELVNqSwgRTuIYUBUlhBCr_vAfUBD-CEDZwwAAZv4IRlils44QGcsIbTY3T58eji4Nhq-3JY3KVBDQYZS1KHxIR5SUgSN3FVWAEPBfdoEAsQ6TBFmUNoDNqOIHYqBHfUO_oQPiBP0E4hC_EM4QAMFOaEbBry1OWpE_IwodTnUzcVzLHdMXrXETFamvIrkTZbqR8pwke2F2nCj9GbjsQRCEh16sUKIRt4wieB8nMTZ4yeGtr3S3W8en7jzAt0d4PXl2inLhvxCtTQOn6tUfET1pyMdg |
link.rule.ids | 315,783,787,27938,27939 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rho-Associated+Kinase+Inhibitor+Eye+Drop+%28Ripasudil%29+Transiently+Alters+the+Morphology+of+Corneal+Endothelial+Cells&rft.jtitle=Investigative+ophthalmology+%26+visual+science&rft.au=Okumura%2C+Naoki&rft.au=Okazaki%2C+Yugo&rft.au=Inoue%2C+Ryota&rft.au=Nakano%2C+Shinichiro&rft.date=2015-11-01&rft.eissn=1552-5783&rft.volume=56&rft.issue=12&rft.spage=7560&rft_id=info:doi/10.1167%2Fiovs.15-17887&rft_id=info%3Apmid%2F26618648&rft.externalDocID=26618648 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1552-5783&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1552-5783&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1552-5783&client=summon |